Compare Medtronic PLC (MDT) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Stryker Corporation — how do they compare? Medtronic PLC trades at $82.54 (market cap $106.61B), while Stryker Corporation trades at $315.82 (market cap $122.35B). The key difference: Medtronic PLC and Stryker Corporation are close in size by market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | SYK | |
|---|---|---|
Market Cap | $106.61B | $122.35B |
Sector | Health | Technology |
52-Week High | $105.35 | $403.53 |
52-Week Low | $73.75 | $282.58 |
Enterprise Value | $125.36B | $134.10B |
Dividend Yield | 3.46% | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Stryker (SYK) trades at $319.14, down 0.23% on the day, with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust profitability with 63.83% gross margins and 13.21% net margins. Recent Q1 2026 earnings missed expectations due to a cybersecurity disruption, but management maintained full-year guidance. Analyst consensus remains strongly bullish with a $388.44 price target and 74% buy ratings.
The stock presents a compelling opportunity for long-term investors given its strong fundamentals and innovation pipeline, though near-term technical weakness and competitive pressures warrant caution. Upside potential exists from continued Mako robotics adoption and market share gains, while risks include cybersecurity vulnerabilities and integration challenges from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
